BioCentury
ARTICLE | Clinical News

Olaptesed pegol: Additional Phase IIa data

July 28, 2014 7:00 AM UTC

Data from 20 evaluable patients with relapsed MM in an open-label, dose-escalation, European Phase IIa trial showed that olaptesed pegol in combination with Velcade bortezomib and dexamethasone led t...